Diabetes Researchers Halt Grant Reviews in ADA Boycott

Members of the American Diabetes Association have launched a boycott of the organization, including a halt to grant reviews and peer review of new submissions to its flagship journal Diabetes Care, after five scientists were removed from the ADA's annual conference in June.

The American Diabetes Association is facing an organized withdrawal of labor by the very researchers it depends on. Following the removal of five scientists from the ADA's annual conference in June, members have launched a boycott of the organization that includes refusing to review grant applications and declining to peer-review new articles submitted to Diabetes Care, the association's flagship journal, as reported by Fierce Biotech.

That is a narrow-sounding action with wide consequences. Scientific societies like the ADA run on unpaid volunteer labor. The people who score grant applications and referee manuscripts are the same senior investigators who present at the annual meeting, sit on committees and, in many cases, apply for the association's own funding. When a critical mass of them steps back at once, the organization does not lose a headline — it loses its throughput.

What a grant-review boycott actually stops

Research charities do not simply write checks. Applications are triaged, assigned to study sections, read by subject-matter specialists, scored, discussed and ranked. Each of those steps requires a researcher with the right expertise who is free of conflicts with the applicant — a pool that, in a field as specialized as diabetes and metabolic disease, is not deep.

Pull reviewers out of that process and the funding cycle does not merely slow; it stalls at a specific point. Applications can still be submitted and administratively checked, but they cannot be scored. Awards cannot be ranked. And because grant cycles are calendar-locked to academic hiring and trainee appointments, a delay measured in months can cost a postdoctoral researcher a position or force a lab to shelve a project.

The people most exposed here are not the ADA's leadership. They are early-career scientists whose salaries ride on award decisions, and the patients whose treatment questions those projects were designed to answer. That asymmetry is the uncomfortable core of any academic boycott: the pressure is applied to an institution, but the pain lands first on the least powerful participants.

Why withholding peer review hits a journal hardest

Diabetes Care occupies an unusual position. Clinical journals in a defined therapeutic area function as the field's record of what works — the place where trial results, treatment-guideline evidence and real-world outcomes data are stress-tested before they enter practice. That standing rests entirely on the credibility of the reviewers who vet each paper.

A journal that cannot recruit qualified referees has three unappealing options: wait, widen the reviewer pool to less-expert readers, or push papers through with thinner scrutiny. Each erodes the asset. Authors notice review times lengthening and send their best work elsewhere. Competing journals in the same space are happy to take it. Reputational damage of this kind compounds quietly and is slow to reverse, because the signal a journal sends is built over years of consistent handling.

Publishing revenue matters too. Society journals are frequently among the most reliable income lines a nonprofit medical association has, funding education programs and advocacy that subscriptions and meeting fees alone would not cover. A sustained submission slowdown is therefore a financial question as well as a scientific one.

The annual meeting is the pressure point to watch

The ADA's Scientific Sessions is one of the anchor events of the metabolic-disease calendar, and it is where the conflict began. Large annual meetings serve several constituencies at once: academics presenting data, drug and device manufacturers exhibiting and sponsoring, clinicians collecting continuing-education credit, and journalists and investors watching for readouts that move treatment practice.

Those constituencies are linked. Industry sponsors buy exhibit space and symposium slots because the scientific audience shows up. If a meaningful share of the research community signals it will not participate, the commercial side of the meeting becomes harder to sell, and the late-breaking abstract sessions that give the event its news value become thinner. Diabetes is not a quiet field right now — incretin-based therapies have made it one of the most commercially significant areas in medicine — so a weakened forum in the specialty would not go unnoticed by the companies with data to present.

The practical test will be whether the boycott holds through the next submission and abstract cycle, and whether it stays confined to grant review and manuscript refereeing or extends to abstract submission, committee service and membership renewals. Escalation along those lines would move the dispute from an internal governance fight into something visible to the wider field.

Governance disputes are becoming a recurring risk for societies

Professional and scientific associations have spent recent years navigating an uncomfortable combination: members who expect a voice in how the organization conducts itself, and boards that also answer to sponsors, regulators and legal counsel. Decisions about who may speak at a meeting — and who may be removed from one — sit exactly at that seam.

What distinguishes a scientific society from most institutions is that its authority is entirely delegated. The ADA's convening power, its journal's standing and its grant program's credibility all exist because researchers agree to supply them. There is no contract compelling anyone to referee a paper. When members withdraw that consent collectively, the organization has limited tools beyond negotiation, because it cannot simply purchase replacements of equivalent standing.

What to monitor from here

Several markers will indicate whether this is a short flare or a durable rupture. Watch for a formal response from the ADA's board addressing the June removals. Watch Diabetes Care's handling times and whether editorial board members resign — editor departures are the clearest public signal that a journal-level dispute has become structural. Watch whether other societies in adjacent fields see similar organizing, which would suggest a broader shift in how members exert leverage.

For the drugmakers and device companies working in metabolic disease, the near-term operational effect is limited: regulators, not societies, decide approvals, and industry-sponsored trials publish across many journals. Broader markets were untroubled by the dispute. The S&P 500, tracked by SPY, closed at $764.29, up 0.85% on the day, with the Nasdaq 100 proxy QQQ at $714.88, up 0.87%, and the Dow 30 proxy DIA at $525.79, up 0.97%, as of the last trade on Friday, 11 September 2026.

The longer-term stake is the infrastructure itself. Guidelines, standards of care and the peer-reviewed evidence base that payers and prescribers lean on are produced by the same volunteer system now being withheld. If it does not restart cleanly, the cost will not show up in a single quarter — it will show up in slower publication of the trial results that change how diabetes is treated.

Key facts

• Trigger: Five scientists removed from the ADA's annual conference in June
• Action: Members halting grant reviews and peer review for Diabetes Care
• Journal affected: Diabetes Care, the ADA's flagship publication
• Market backdrop: S&P 500 proxy SPY closed at $764.29, +0.85%, as of 11 Sep 2026 20:00 GMT

Frequently asked questions

What set off the boycott of the American Diabetes Association?

The dispute stems from the removal of five scientists from the ADA's annual conference in June. In the fallout, members of the association organized a boycott, and that action has since escalated to include withholding two forms of unpaid volunteer labor the organization relies on: grant application review and peer review of manuscripts.

What exactly are the boycotting scientists refusing to do?

Two things specifically. They are halting the review of grant applications submitted to the ADA, and they are declining to peer-review new articles submitted to Diabetes Care, the association's flagship journal. Both functions are performed by volunteer researchers rather than paid staff, which is what gives the action its leverage.

Why does refusing peer review matter so much?

Scientific journals depend on qualified specialists agreeing to referee submissions without payment. Without them, a journal must either delay publication, widen its reviewer pool to less-expert readers, or apply thinner scrutiny. Each option damages the journal's credibility, and authors typically respond by sending their strongest work to competing publications instead.

Who is hurt most by a grant-review stoppage?

Early-career researchers are the most exposed. Grant cycles are tied to academic calendars, so a delay in scoring and ranking applications can cost a postdoctoral scientist a position or force a laboratory to shelve a project. The institution being pressured is not the party that feels the disruption first.

Does this affect diabetes drug approvals?

Not directly. Regulatory approval decisions are made by government agencies based on trial data submitted by sponsors, not by professional societies. Industry-sponsored studies also publish across many journals. The longer-term risk is to the peer-reviewed evidence base and treatment guidelines that clinicians and payers rely on.

What would signal that the dispute is deepening?

Key markers include a formal response from the ADA board on the June removals, resignations from the Diabetes Care editorial board, lengthening manuscript handling times, and any extension of the boycott to abstract submissions, committee service or membership renewals ahead of the next annual conference cycle.

Sources

• Scientists boycott American Diabetes Association as fallout of June conference fracas escalates — Fierce Biotech

Photo: Jan van der Wolf · Pexels Licence — source